Department of Pathology, University Hospital Campus Bio-Medico, Rome, Italy.
Sikl's Department of Pathology, Medical Faculty in Pilsen, Charles University in Prague, Pilsen, Czech Republic; and.
Am J Dermatopathol. 2023 Feb 1;45(2):117-122. doi: 10.1097/DAD.0000000000002332. Epub 2022 Dec 19.
BAP1-inactivated melanocytic tumors represent a subset of epithelioid melanocytic neoplasms resulting from biallelic inactivation of the BAP1 gene and by a driver mutation that activate the MAP kinase pathway, most commonly BRAFV600E. They occur sporadically or, less common, in the setting of BAP1 tumor predisposition syndrome caused by a BAP1 germline mutation that predisposes to several malignancies including cutaneous and uveal melanoma. To date, only few cases of BAP1-inactivated melanomas have been reported. We present a case of a 35-year-old woman presented with a melanocytic lesion microscopically composed of 3 distinct melanocytic populations, suggesting a stepwise progression model to melanoma from a conventional nevus through a melanocytoma stage. This progression was also supported from a molecular viewpoint given BRAFV600E, BAP1, and TERT-p hot spot mutations detected by targeted mutational analysis. Four atypical melanocytic lesions were removed from the patient's back, and the same A BAP1 c.856A>T, p.(Lys286Ter) mutation was detected on either tumoral or normal tissue samples. To the best of our knowledge, this is the first case of BAP1-inactivated melanoma with a documented TERT-p hot spot mutation manifesting as the first presentation of BAP1 tumor predisposition syndrome.
BAP1 失活的黑色素瘤代表了上皮样黑色素瘤的一个亚组,这些肿瘤是由于 BAP1 基因的双等位基因失活和激活 MAP 激酶途径的驱动突变(最常见的是 BRAFV600E)引起的。它们偶尔发生,或者更常见于 BAP1 肿瘤易感性综合征,这是由 BAP1 种系突变引起的,易患多种恶性肿瘤,包括皮肤和葡萄膜黑色素瘤。迄今为止,仅报道了少数 BAP1 失活的黑色素瘤病例。我们报告了一例 35 岁女性的黑色素瘤病例,其显微镜下的黑色素瘤由 3 种不同的黑色素细胞群体组成,提示从常规痣到黑色素细胞瘤阶段逐步进展为黑色素瘤的模型。从分子角度来看,这种进展也得到了支持,因为通过靶向突变分析检测到 BRAFV600E、BAP1 和 TERT-p 热点突变。从患者背部切除了 4 个不典型的黑色素瘤病变,在肿瘤或正常组织样本中均检测到相同的 A BAP1 c.856A>T,p.(Lys286Ter)突变。据我们所知,这是首例有记录的 TERT-p 热点突变的 BAP1 失活黑色素瘤病例,表现为 BAP1 肿瘤易感性综合征的首次表现。